Objective: To determine whether hospice enrollment at the time of a terminal admission alters the length of stay (LOS) or costs compared with patients not enrolled in hospice. Methods: Retrospective chart review of all nontraumatic inpatient deaths of patients with a previous admission in the preceding 12 months at an academic hospital. Results: 209 patients had a nontraumatic death and an admission in the year prior to the terminal admission. Patients enrolled in hospice had a shorter LOS (P ¼ .02) and lower cost (P < .0001) than patients not enrolled at the time of their terminal admission. Conclusions: Enrollment in hospice during a terminal admission decreased cost and LOS. Hospice may be a way to provide more cost-effective, appropriate care to dying patients.
Introduction
There is increasing evidence that enrollment in hospice decreases cost, improves patient and family satisfaction, reduces hospital days, and improves the odds that a patient will die in a nonhospital setting. 1, 2 While patients enrolled in hospice may be more likely to die at home than patients not enrolled in hospice, 3 some still die in the hospital for a variety of reasons including admission for the management of symptoms (eg, pain crisis or terminal delirium), patient and family preference, and as an unexpected consequence (eg, someone panics and calls 911). 4 We hypothesized that patients who were admitted and died in the hospital while under hospice care had a decreased cost and length of stay (LOS) compared to people who died in the hospital and did not have hospice support.
Methods

Study Selection and Population
Approval of this study was granted by the University of Iowa Hospitals and Clinics (UIHC) Institutional Review Board. We conducted a retrospective review of all adult inpatient deaths at the UIHC in 2009. Inclusion criteria were an inpatient admission in the previous 12 months. Exclusion criteria were death due to trauma. For each eligible patient, we recorded age, sex, race, date of death, primary and secondary diagnoses, hospice enrollment, LOS, and total hospital costs on both the final discharge summary and the discharge summary prior to the terminal admission. We also determined which patients were eligible for hospice based on National Hospice and Palliative Care Organization criteria at the time of their admission prior to their terminal admission (results in previous publication). 5 
Statistical Analysis
Data were entered in a database using coded identifiers. Statistical analysis was conducted using SAS 9.2 for Windows (SAS 9.2, SAS Institute, Inc, Cary, North Carolina). Standard descriptive statistics were used with Wilcoxon rank-sum tests to describe differences in age, cost, and LOS for patients enrolled in hospice versus patients not enrolled in hospice. The LOS and cost for hospice patients were also compared to those of nonhospice patients with diagnoses (primary or secondary) of cancer. This was done with Wilcoxon rank-sum tests as well. Wilcoxon rank-sum tests were used because of the small number of hospice enrolled patients (n ¼ 7). Due to this small n, visually comparing the distributions of the samples was difficult, so significant results may be influenced by factors other than those with and without hospice enrollment truly having different medians. To compare the cost and LOS of patients with palliative care versus those without it, 2 independent sample t tests with log transformations of the variables of interest were performed (log transformations were used to better approximate normality of the distributions). The Pearson chisquare test and the Fisher exact test were used to test for significant differences in proportions of sex, race, primary diagnosis, and type of insurance/payer for patients who were hospice eligible versus those who were ineligible. More specifically, the Fisher exact test was used to test proportions that did not meet the assumptions of the Pearson chi-square test due to small cell sizes. These proportions included terminal diagnosis, race, and type of insurance/payer. The number of days between penultimate and terminal admission was compared between those who were hospice eligible and those who were ineligible as well, and a 2 independent sample t test with a log transformation of the variable of interest was used. Spearman correlation was used to determine and test the monotonic relationship between cost observed and the number of secondary diagnoses. Spearman was used in place of Pearson correlation due to concerns regarding the normality of the data. Corresponding P values were recorded, with significance being considered at the standard level of .05.
Results
Patient Characteristics
This study involved patients who were admitted and died at a large academic institution. The overall demographics and findings are characterized in a previous publication. 5 Briefly, of the 688 adult patients who died during 2009, 209 (30%) had a nontraumatic death and a hospital admission in the 12 months preceding the terminal admission. Of all, 60% (n ¼ 126) were hospice eligible during the admission proceding the terminal admission. Days between the previous admission and terminal admission were greater for patients not eligible for hospice (P <.0001), with the mean number of days being 62.80 (median 42) for hospice eligible patients and 130.16 (median 96) for hospice ineligible patients. There was no significant association between gender, race, or insurance and hospice eligibility status; however, primary diagnosis was associated (P < .001).
The majority of patients had multiple secondary diagnoses listed on the discharge summary from the terminal admission (number 0-8, mean 2.88, and standard deviation 1.73). The breakdown of the primary terminal diagnosis is 17% (n ¼ 36) cardiac/vascular, 20% (n ¼ 41) respiratory, 8% (n ¼ 17) gastrointestinal, 13% (n ¼ 28) cancer, 3% (n ¼ 7) renal, 27% (n ¼ 56) infection, 1% (n ¼ 3) rheumatoid/autoimmune, and 10% (n ¼ 21) neurological. Of all, 86 patients had cancer listed as either a primary or a secondary diagnosis.
Patients Enrolled in Hospice at the Time of the Terminal Admission
Seven patients had enrolled in hospice prior to their terminal admission. All had cancer. Terminal diagnosis listed in the discharge summary included cancer (n ¼ 3), respiratory causes (n ¼ 3), and sepsis (n ¼ 1).
Hospital Costs and LOS
No significant difference in age (P ¼ .05) was found between the patients enrolled in hospice and those not enrolled in hospice. The 7 patients enrolled in hospice demonstrated a decreased cost (P < .0001) and LOS (P ¼ .02) during the terminal admission compared to patients not enrolled in hospice ( Table 1) . The same 7 patients did not demonstrate a decreased cost or LOS during the admission prior to the terminal admission. It is worth noting that no patients were enrolled in hospice during the admission prior to the terminal admission. The decrease in cost and LOS was maintained when the 7 patients enrolled in hospice were compared with only the other patients that had a diagnosis (primary or secondary) of cancer (P < .001, P ¼ .0307, respectively). We also identified a correlation between the number of secondary diagnoses and the observed cost. Increased number of secondary diagnosis was correlated with an increased cost (Spearman correlation value ¼ .32, P < .001).
Patients who received a palliative care consult during the terminal admission also demonstrated a decreased cost (mean cost $41 859, n ¼ 98) but not a decreased LOS (mean LOS 13.16 days, n ¼ 98) compared to patients who did not receive 
Conclusions
Patients enrolled in hospice at the time of a terminal admission demonstrated a striking difference in LOS and cost when compared to patients who were not enrolled in hospice. This saving was maintained when the pool was decreased to include only patients with cancer. This finding is different from Tan's finding that there was no difference in cost when patients with cancer are admitted from hospice, but his study was not looking at terminal admissions. 6 It is similar to previous studies that have shown hospice enrollment demonstrates decreased costs at the end of life as well as decreased LOS and intensive care utilization while subsequently increasing the quality and satisfaction of the care received. [7] [8] [9] [10] [11] [12] This may be due to any number of factors, including the tendencies for hospice patients to have had: goals of care discussions leading to clearer goals of care; a discussion of prognosis leading to an understanding of the terminal nature of the condition; and improved patient monitoring and advocacy.
In addition, in support of recent findings regarding palliative care, 13 we also confirmed that a palliative care consult, during a terminal admission, has a positive benefit on cost. This study was exploratory in nature and as such has clear limitations. These include the retrospective study design that was designed to capture only patients who have had a previous hospitalization. It does not include the 479 patients who died in the hospital in 2009 without having a previous admission. The full sample may have included more hospice patients, but we feel that is unlikely since repeat hospitalizations can be a marker of disease severity and should make recognition that a patient may be hospice eligible more likely. We also had a very small sample size of hospice patients which may make the results less reliable; however, given the robust difference found we think that is unlikely. It would have been interesting to know why patients were being enrolled in hospice but that information was not consistently available in the electronic medical record.
It was striking to us how few inpatients died under hospice care. The majority of the patients had complex medical conditions yet were not enrolled in a beneficial and potentially life-extending service. The number of palliative care consults increased from the admission prior to the terminal admission, indicating that the primary team was more likely to recognize how ill a patient was during the terminal admission. Unfortunately by this time, it is typically too late for an effective hospice referral. Our previous article illustrated that hospice eligibility was often not considered even in patients with multiple serious medical illnesses. It is difficult to know how to overcome that hurdle. Educational efforts and further research needs to be done.
These data have implications for the health care system. As we strive to provide cost-effective, evidence-based care, hospice may be an effective tool to meet those objectives in patients with a serious life-limiting illness. Increasing hospice referrals and enrollment rates in appropriate patients is likely to be beneficial to our patients and their families, as well as, to our entire health care system.
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